Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2

NCT05514717 is registered in ClinicalTrials.gov with Day One Biopharmaceuticals, Inc. as lead sponsor.

NCT NCT05514717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05514717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2
Lead sponsor
Day One Biopharmaceuticals, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
January 24, 2023
Completion date
May 22, 2026
Enrollment
57 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

her2 low breast cancer, her2-positive breast cancer, her2-positive colorectal cancer, her2-positive gastric cancer, her2-positive non-small cell lung cancer, her2-positive tumors